Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genovate Biotechnology Co., Ltd.,
With
Otsuka Pharmaceutical Co., Ltd.
Age
12–25
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Male or female in age between 12 and 25 years old.
2. Clinical diagnosis of DSM-IV of psychotic symptom (e.g. schizophrenia or other psychotic disorders such as schizophreniform disorder, schizoaffective disorder, delusional disorder, shared psychotic disorder, bipolar disorder with psychotic feature or psychotic disorder not otherwise specified.).
3. CGI-S ≧ 3 at screening visit.
4. Informed Consent was obtained from the subject (and legal guardian as if necessary).
You may not be if
1. Pregnant or breast feeding women or planning a pregnancy.
2. Patient received electroconvulsive therapy within 4 weeks before the screening visit.
3. Patient has a history of hypersensitivity or allergy to investigated drug.
4. A known severe adverse event related to any antipsychotic medication (including but not limited to haloperidol, chlorpromazine, thioridazine, pimozide, risperidone, quetiapine, ziprasidone).
5. Any clinical condition or significant concurrent disease judged by the investigator to complicate the evaluation of the study treatment.
